查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1317759

多發性硬化症市場：按治療方法（注射、口服）、按用途（醫院、研究）分類 - 全球預測 2023-2030

Multiple Sclerosis Market by Treatment Modality (Injectable Agents, Oral Agents), Application (Hospital, Research) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球多發性硬化症市場預計到2023年將大幅成長至166.9億美元，年複合成長率為8.23%，到2030年將達到290.9億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球多發性硬化症市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.多發性硬化症的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球多發性硬化症市場的阻礙因素和影響為何？

3. 在預測期內，全球多發性硬化症市場需要投資哪些產品/細分市場/用途/領域？

4. 全球多發性硬化症市場的競爭策略為何？

5. 全球多發性硬化症市場的技術趨勢和法律規範是什麼？

6.全球多發性硬化症市場主要供應商的市佔率是多少？

7. 哪些型態和策略措施被認為適合進入全球多發性硬化症市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 對全球研發活動的大力投資
      • 政府的有利支持提高人們的意識
      • 年輕人和老年人多發性硬化症的發生率增加
    • 抑制因素
      • 藥品價格相對較高
    • 機會
      • 對 Copaxone 和 Tysabri 等口服藥物的偏好增加
      • 主要市場參與企業新藥研發管線的出現
    • 任務
      • 嚴格的藥品核准法規政策
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 多發性硬化症市場：治療方法

  • 介紹
  • 注射
  • 口服劑

第7章 多發性硬化症市場：依用途

  • 介紹
  • 醫院
  • 研究

第8章 美洲多發性硬化症市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太多發性硬化症市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲多發性硬化症市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-036C5CF3A89E

The Global Multiple Sclerosis Market is forecasted to grow significantly, with a projected USD 16.69 billion in 2023 at a CAGR of 8.23% and expected to reach a staggering USD 29.09 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Multiple Sclerosis Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Multiple Sclerosis Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Treatment Modality, market is studied across Injectable Agents and Oral Agents. The Oral Agents is projected to witness significant market share during forecast period.

Based on Application, market is studied across Hospital and Research. The Research is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Multiple Sclerosis Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Multiple Sclerosis Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiple Sclerosis Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiple Sclerosis Market?

4. What is the competitive strategic window for opportunities in the Global Multiple Sclerosis Market?

5. What are the technology trends and regulatory frameworks in the Global Multiple Sclerosis Market?

6. What is the market share of the leading vendors in the Global Multiple Sclerosis Market?

7. What modes and strategic moves are considered suitable for entering the Global Multiple Sclerosis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Multiple Sclerosis Market, by Treatment Modality, 2022 vs 2030
  • 4.3. Multiple Sclerosis Market, by Application, 2022 vs 2030
  • 4.4. Multiple Sclerosis Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Robust investment in research and development activities globally
      • 5.1.1.2. Favorable government support to increase the awareness among people
      • 5.1.1.3. Rising incidence of MS in young and elderly people
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing preference for oral drugs such as Copaxone and Tysabri
      • 5.1.3.2. Emerging novel pipeline of drugs by key market players
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies for drug approval
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Multiple Sclerosis Market, by Treatment Modality

  • 6.1. Introduction
  • 6.2. Injectable Agents
  • 6.3. Oral Agents

7. Multiple Sclerosis Market, by Application

  • 7.1. Introduction
  • 7.2. Hospital
  • 7.3. Research

8. Americas Multiple Sclerosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Sclerosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Sclerosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE SCLEROSIS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2022 VS 2030 (%)
  • FIGURE 5. MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. MULTIPLE SCLEROSIS MARKET DYNAMICS
  • FIGURE 8. MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 5. MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 8. MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 97. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 98. MULTIPLE SCLEROSIS MARKET LICENSE & PRICING